BR112017009584A2 - tratamento de retinite pigmentosa com n-acetilcisteína amida - Google Patents

tratamento de retinite pigmentosa com n-acetilcisteína amida

Info

Publication number
BR112017009584A2
BR112017009584A2 BR112017009584A BR112017009584A BR112017009584A2 BR 112017009584 A2 BR112017009584 A2 BR 112017009584A2 BR 112017009584 A BR112017009584 A BR 112017009584A BR 112017009584 A BR112017009584 A BR 112017009584A BR 112017009584 A2 BR112017009584 A2 BR 112017009584A2
Authority
BR
Brazil
Prior art keywords
retinitis pigmentosa
acetylcysteine amide
treatment
acetylcysteine
amide
Prior art date
Application number
BR112017009584A
Other languages
English (en)
Inventor
Hartman Daniel
A Campochiaro Peter
Original Assignee
Nacuity Pharmaceuticals Inc
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nacuity Pharmaceuticals Inc, Univ Johns Hopkins filed Critical Nacuity Pharmaceuticals Inc
Publication of BR112017009584A2 publication Critical patent/BR112017009584A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

a presente invenção inclui um método para o tratamento de retinite pigmentosa, em um ser humano que compreende a administração ao humano de uma quantidade terapeuticamente eficaz de n-acetilcisteína amida (naca). de acordo com uma modalidade, a presente invenção fornece um método para o tratamento de retinite pigmentosa em um animal que compreende a administração ao animal de uma quantidade terapeuticamente eficaz de n-acetilcisteína amida (naca)
BR112017009584A 2014-11-07 2015-11-06 tratamento de retinite pigmentosa com n-acetilcisteína amida BR112017009584A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462076594P 2014-11-07 2014-11-07
PCT/US2015/059589 WO2016073931A1 (en) 2014-11-07 2015-11-06 Treatment of retinitis pigmentosa with n-acetylcysteine amide

Publications (1)

Publication Number Publication Date
BR112017009584A2 true BR112017009584A2 (pt) 2017-12-26

Family

ID=55909913

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017009584A BR112017009584A2 (pt) 2014-11-07 2015-11-06 tratamento de retinite pigmentosa com n-acetilcisteína amida

Country Status (11)

Country Link
US (2) US20180296503A1 (pt)
EP (2) EP4000612A1 (pt)
JP (4) JP2017533969A (pt)
KR (3) KR20230152177A (pt)
CN (2) CN108498495A (pt)
AU (4) AU2015342831B2 (pt)
BR (1) BR112017009584A2 (pt)
CA (1) CA2967327C (pt)
HK (1) HK1252822A1 (pt)
RU (1) RU2711913C2 (pt)
WO (2) WO2016073829A2 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752593B2 (en) 2018-12-28 2020-08-25 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
WO2016077467A1 (en) 2014-11-11 2016-05-19 The Johns Hopkins University Biomarkers useful in the treatment of subjects having diseases of the eye
EP3684756A4 (en) 2017-09-20 2020-10-28 NaCuity Pharmaceuticals, Inc. SYNTHESIS OF N-ACETYLCYSTEIN AMIDE AND ITS DERIVATIVES
US11548851B2 (en) 2017-09-20 2023-01-10 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide and derivatives thereof
US11091433B2 (en) 2017-09-20 2021-08-17 Nacuity Pharmaceutials, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
WO2019103915A1 (en) * 2017-11-21 2019-05-31 The Johns Hopkins University Compositions and methods for treatment of eye diseases
WO2020011607A1 (en) * 2018-07-09 2020-01-16 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
CN109096161B (zh) * 2018-08-24 2020-10-27 武汉远大弘元股份有限公司 一种n-乙酰半胱氨酸的制备方法
US10807973B2 (en) 2018-12-28 2020-10-20 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
EP3908341A4 (en) * 2019-01-11 2022-03-02 NaCuity Pharmaceuticals, Inc. TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA)
WO2021151044A1 (en) * 2020-01-24 2021-07-29 Nacuity Pharmaceuticals, Inc. Prodrug for the treatment of disease and injury of oxidative stress

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090234011A1 (en) * 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
CN101232877A (zh) * 2005-04-21 2008-07-30 格伦·A·戈尔茨坦 治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺（nac酰胺）
US20150148423A1 (en) * 2012-04-26 2015-05-28 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury

Also Published As

Publication number Publication date
US20170333375A1 (en) 2017-11-23
KR20230152177A (ko) 2023-11-02
AU2019261762B2 (en) 2021-06-10
CA2967327A1 (en) 2016-05-12
JP2023145734A (ja) 2023-10-11
JP2021193119A (ja) 2021-12-23
AU2019261762A1 (en) 2019-11-28
AU2015342831B2 (en) 2019-09-12
AU2021225263A1 (en) 2021-09-30
RU2017119230A3 (pt) 2018-12-10
JP2017533969A (ja) 2017-11-16
JP2020023549A (ja) 2020-02-13
EP4000612A1 (en) 2022-05-25
CN107426997A (zh) 2017-12-01
CN108498495A (zh) 2018-09-07
RU2711913C2 (ru) 2020-01-24
KR20170109527A (ko) 2017-09-29
US20180296503A1 (en) 2018-10-18
CA2967327C (en) 2020-04-28
EP3214934A4 (en) 2018-06-20
EP3214934A1 (en) 2017-09-13
WO2016073829A9 (en) 2016-06-23
KR20220039853A (ko) 2022-03-29
AU2021225263B2 (en) 2023-11-02
RU2017119230A (ru) 2018-12-10
HK1252822A1 (zh) 2019-06-06
WO2016073829A2 (en) 2016-05-12
AU2015342831A1 (en) 2017-05-25
WO2016073931A1 (en) 2016-05-12
AU2024200436A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
BR112017009584A2 (pt) tratamento de retinite pigmentosa com n-acetilcisteína amida
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
PH12017500746B1 (en) Carbidopa and l-dopa prodrugs and their use to treat parkinson's disease
PH12016501978A1 (en) Treatment of nafld and nash
CO2017011564A2 (es) Métodos y kits para tratar la depresión
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
BR112017011900A2 (pt) tratamento de ataques com fosfatase alcalina recombinante
BR112019005040A2 (pt) aplicação de pridopidina para tratamento de síndrome de rett
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
CL2020000383A1 (es) Composiciones de aminoácidos para el tratamiento de lesión neuronal.
MX2019002190A (es) Uso de pridopidina para tratar distonías.
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
EP4364743A3 (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
BR112018008882A2 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
BR112018003836A2 (pt) combinações de inibidor de btk para tratar mieloma múltiplo
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
BR112016012248A2 (pt) método de tratamento de nefropatia
BR112019006504A2 (pt) regime de dosagem de avelumabe para o tratamento de câncer
BR112018007768A2 (pt) composições e métodos para tratamento de homocistinúria
BR112017018758A2 (pt) alteração do metabolismo de esteroide para tratamento de doença dependente de esteroide

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]